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Abstract: Biological markers are already used in the diagnosis and treatment of cardiovascular 
disease and cancer. Biomarkers have great potential use in the clinic as a noninvasive means 
to make more accurate diagnoses, monitor disease progression, and create personalized treat-
ment regimes. Asthma is a heterogeneous disease with several different phenotypes, generally 
triggered by multiple gene-environment interactions. Pulmonary function tests are most often 
used objectively to confirm the diagnosis. However, airflow obstruction can be variable and 
thus missed using spirometry. Furthermore, lung function measurements may not reflect the 
precise underlying pathological processes responsible for different phenotypes. Inhaled corti-
costeroids and β2-agonists have been the mainstay of asthma therapy for over 30 years, but the 
heterogeneity of the disease means not all asthmatics respond to the same treatment. High costs 
and undesired side effects of drugs also drive the need for better targeted treatment of asthma. 
Biomarkers have the potential to indicate an individual’s disease phenotype and thereby guide 
clinicians in their decisions regarding treatment. This review focuses on biomarkers of airway 
inflammation which may help us to identify, monitor, and guide treatment of asthmatics. We 
discuss biomarkers obtained from multiple physiological sources, including sputum, exhaled 
gases, exhaled breath condensate, serum, and urine. We discuss the inherent limitations and 
benefits of using biomarkers in a heterogeneous disease such as asthma. We also discuss how 
we may modify our study designs to improve the identification and potential use of potential 
biomarkers in asthma.
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Background
Modern technology allows the measurement of a myriad of biological parameters. 
Many of these biological markers (biomarkers) have found clinical and regulatory 
acceptance as substitutes for clinical endpoints. Such surrogate endpoints are particu-
larly useful when the clinical endpoint in question is extreme or relatively rare, eg, 
survival, myocardial infarction, or cancer recurrence. Reduction of elevated arterial 
blood pressure has been used for decades to indicate a lower incidence of conges-
tive heart failure and stroke. Serum cholesterol is also commonly used as an indirect 
measure of coronary artery disease without the need for invasive exploratory surgery. 
Thus, a biomarker is a candidate surrogate endpoint, able to indicate presence of dis-
ease without waiting for extreme clinical endpoints to occur, and avoiding the need 
for potentially invasive surgery.
The National Institutes of Health defines a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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pathogenic processes, or pharmacologic responses to a thera-
peutic intervention”.1
The ability to diagnose or treat a disease by measuring 
a biological molecule from a noninvasive source, such as 
blood, urine, or exhaled breath, has a great advantage over 
traditional pathological techniques because direct access 
to diseased tissue is not required. If we were designing a 
“perfect” biomarker, it should be a mediator in a biochemi-
cal pathway necessary for development of the disease rather 
than an epiphenomenon and, as such, should act as a potential 
target for therapy. Levels of the marker should be low and 
stable in normal individuals and measurably higher in patients 
with disease, a difference which should be consistent between 
individuals with disease. Lastly, the technique required to 
measure the biomarker should be rapid, straightforward, and 
relatively inexpensive.
In the cardiovascular field, Maisel describes the ideal 
biomarker as a “tool that should aid the physician in one or 
more of the following: diagnosis and subsequent risk strati-
fication, risk stratification for secondary prevention, guiding 
selection of therapy, and, finally, in some cases, serving as a 
target for therapy”.2 In addition to diagnosis and treatment, 
targeting a biomarker can act as a predictor. If a rise in a 
biomarker precedes a worsening of a condition, this advance 
warning may allow enough time for treatment to be adjusted 
to avoid an exacerbation. In chronic obstructive pulmonary 
disease (COPD) for example, plasma levels of the cardiac 
dysfunction biomarkers, troponin-T and N-terminal probrain 
natriuretic peptide, are often raised in patients suffering 
from acute exacerbations and are associated with increased 
mortality.3 Although this was a retrospective study of patients 
admitted to hospital after the onset of a COPD exacerbation, 
it is possible that a rise in plasma levels of these two biomark-
ers may precede the worsening of symptoms, and therefore 
act as a predictor of COPD exacerbation.
Clinical assessment of asthma
Pulmonary function tests are routinely used clinically to diag-
nose asthma. Forced expiratory volume in one second (FEV1) 
is a measure of airflow and is influenced largely by resistance 
in the airways. During an “asthma attack”, the airways nar-
row as a result of mucus hypersecretion and smooth muscle 
contraction, which results in a sharp increase in airway 
resistance and reduction in FEV1. In the clinic, this can be 
reproduced by exposing patients with asthma to nonspecific 
smooth muscle contractile agonists such as methacholine.   
A fall in FEV1 at a relatively low dose of methacholine 
indicates airway hyperresponsiveness. In asthmatic patients, 
this drop in FEV1 can be reversed by inhaled bronchodila-
tors, such as β2-agonists (eg, salbutamol), which relax airway 
smooth muscles. Airway hyperresponsiveness is often used 
as a diagnostic criterion for asthma.
Asthma is rarely fatal but often leads to significant patient 
morbidity. For over 30 years, the mainstay of therapy for 
asthma has been inhaled β2-agonists, which relax the air-
way smooth muscles, causing bronchodilation, and inhaled 
corticosteroids which ameliorate airway inflammation and 
reduce the risk of asthma exacerbations. Steroids are anti-
inflammatory drugs but also have many unwanted side 
effects, particularly at high doses, including weight gain 
due to changes in body metabolism, and a reduction in 
bone mineral density, potentially leading to brittle bones. 
  Therefore, the decision to treat a patient with steroids should 
not be taken lightly.
Asthma is increasingly considered a syndrome, with 
diverse overlapping pathologies and phenotypes contribut-
ing to significant heterogeneity in clinical manifestation, 
disease progression, and treatment response.4 Severe uncon-
trolled asthmatics make up approximately 5%–10% of the 
population of asthmatics, yet they consume around 50% of 
the treatment resources.5 Spirometric tests are incapable of 
exposing the underlying pathologies or phenotypes which 
combine within an individual to produce asthma. In contrast, 
specific biomarkers may enable more accurate subphenotyp-
ing of disease by indicating the pathology in an individual, 
and assist clinicians to tailor better the type and/or dose of 
therapy. In this way, biomarkers have the potential to guide 
more effective personalized treatment regimes in asthma 
(Figure 1).
Airway remodeling in asthma
Although asthma is considered an inflammatory disease, there 
are many structural changes in the airways.   Figure 2 shows 
cross-sections through the large airways of two patients, one 
normal and one a severe asthmatic. The Movat’s pentachrome 
stain clearly highlights the various architectural remodeling 
events occurring in the asthmatic airway. Obstruction of the 
airways by excessive mucus production is a common finding 
in severe asthmatics, and blue staining in the epithelium and 
lumen demonstrates mucous cell hyperplasia, with exces-
sive mucus deposition into the airway. Under the asthmatic 
epithelium, a thicker basement membrane is present which 
contains several different extracellular matrix factors (includ-
ing tenascin-C) compared with normals.6 Deeper into the 
airway, red-stained muscle mass is increased in the asthmatic, 
owing to a combination of smooth muscle hypertrophy and Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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hyperplasia.7 The airways of severe asthmatics also demon-
strate a fibrotic response, with increased connective tissue 
deposition and fibroblast and myofibroblast proliferation. 
Opinion is divided as to whether inflammation precedes 
airway remodeling, or whether the two occur in parallel.8–10 
Evidence tends to favor the latter because, firstly,   remodeling 
occurs very early on in the disease, in some cases in the 
absence of inflammation,11 secondly, there is only a weak 
link between airway inflammation and symptoms,12 and, 
thirdly, epidemiological data demonstrate that steroids do 
not work in all asthmatics.13 In reality, it is likely that effec-
tive therapies will need to target both airway inflammation 
and remodeling.
Inflammation in asthma
As previously mentioned, the rationale for treating severe 
asthmatics with steroids is based on the assumption that 
the disease is driven by uncontrolled airway inflammation. 
The classical paradigm of the acute inflammatory response 
in allergic asthma is shown in Figure 3. Briefly, inhaled 
allergenic antigens are captured by antigen-presenting 
dendritic cells, macrophages, or epithelial cells. Antigens 
presented by these cells are recognized by T cells which 
proliferate and differentiate. Primed Th2 cells bind to B 
cells and release cytokines, that trigger the maturation 
of antigen-specific B cell populations into plasma cells. 
Plasma B cells release antigen-specific IgE that binds to 
IgE receptors on mast cells in the airways, causing release 
of histamine-containing   granules. Extracellular histamine 
released from mast cells binds to membrane receptors on 
airway smooth muscle cells, triggering a rise in intracellular 
calcium, muscle contraction, and airway narrowing. Although 
this paradigm has gained acceptance as an important 
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Figure  1  Heterogeneous  diseases  require  multiple  biomarkers  for  accurate 
diagnosis.  (A)  A  condition  with  a  single  dominant  underlying  pathology  such 
as  myocardial  infarction  can  be  accurately  diagnosed  using  a  single  biomarker   
(eg, troponin T). (B) A heterogeneous disease such as asthma is a result of multiple 
overlapping pathologies, which may vary between individuals. Spirometry can be used 
to diagnose asthma in its broadest clinical terms, but cannot distinguish between 
different subphenotypes of disease. A single biomarker (such as FeNO) can only 
identify a single subphenotype of a heterogeneous disease. (C) A panel of biomarkers 
is required to diagnose the subtype of asthma accurately in an individual.
Abbreviation: FeNO, fractional exhaled nitric oxide.
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Figure  2  The  airways  in  asthma  undergo  significant  structural  remodeling.     
Medium-sized airways from a normal individual and a severe asthmatic patient were 
sectioned and stained using Movat’s pentachrome stain. The epithelium in asthma 
shows  mucous  hyperplasia  and  hypersecretion  (blue),  and  significant  basement 
membrane (Bm) thickening. Smooth muscle (Sm) volume is also increased in asthma. 
Scale bar 100 µm. 
Abbreviations:  Bv,  blood  vessel;  ep,  epithelium;  Bm,  basement  membrane;   
Sm, smooth muscle.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
80
Wadsworth et al
Plasma cells
Release antibodies
Cytokines
BRONCHOCONSTRICTION
INFLAMMATION
Acute Subacute Chronic
B cells
become APCs
Antigens
Mast cells
release cytokines, prostaglandins,
leukotrienes and histamine
Basophils and neutrophils
release cytokines
Eosinophils
release cytokines,
toxic oxygen radicals
and chemotaxic factors
Macrophages
release cytokines
Cytotoxic T cells
and T-helper cells
T cells
release cytokines
Macrophages
become APCs
release cytokines
and histamine
Epithelial cells
become APCs
release cytokines
Figure 3 The inflammatory cascade in asthma. Acute-phase inflammation is triggered when inhaled allergens are captured by antigen-presenting cells (epithelial cells, dendritic 
cells, macrophages) and presented to T cells. Activated Th2 cells trigger B cells to become antibody-producing plasma cells. Plasma cells release antigen-specific IgE which 
binds to ige receptors on mast cells. Activated mast cells degranulate releasing histamine which binds to receptors on airway smooth muscle cells, triggering contraction and 
airway narrowing. Repeated bouts of acute inflammation can lead to chronic inflammation with persistent airway eosinophilia and/or neutrophilia. Image courtesy of EPG 
Online at www.epghealthmedia.com. 
Abbreviation: APC, antigen-presenting cell.
mechanism in asthma, there is significant variation in the 
specific inflammatory cell types involved. In the setting 
of chronic asthma, eosinophils are thought to play a major 
role in maintaining airway inflammation in the long term. 
Neutrophils are occasionally the   predominant inflammatory 
cell present in the airways of chronic asthmatics, suggesting 
multiple underlying pathologies of disease. Neutrophilic 
versus eosinophilic asthma are clinically indistinguishable 
by pulmonary function testing, but such pathological varia-
tion may have important   implications regarding treatment Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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because patients with   neutrophilic inflammation tend to be 
relatively unresponsive to steroid   treatment.13 A rapid and 
definitive method for determining the nature of airways 
inflammation in a diagnosed asthmatic is therefore needed 
to guide selection of therapy.
Direct measures of airway 
inflammation
Tables 1 and 2 summarize the advantages and disadvantages 
of current and potential future biomarkers of airway inflam-
mation for the diagnosis and monitoring of asthma in the 
clinic. These are discussed in more detail below.
Tissue biopsies
To date the most accurate method to assess lung inflammation 
(and remodeling) is by histological examination of lung 
  tissue. Subtypes of inflammatory cells can be identified in 
  tissue   sections using specific stains. Unfortunately the   process 
of taking bronchial biopsies via bronchoscopy is invasive 
and requires experienced, skilled pathologists for tissue 
examination. In addition, clinical studies demonstrate a dis-
connect between the numbers of inflammatory cells counted 
in airway biopsies, and lung function in asthmatics.12
induced sputum
One alternative method of directly assessing airway inflam-
mation is by sputum induction. A patient inhales nebulized 
hypertonic saline to trigger sputum production in the airways. 
The sputum is then coughed out along with any inflammatory 
cells present in the airway lumen. The main assumption is that 
the inflammatory infiltrate in the airway lumen reflects that 
in the tissue. Cytospins of the resulting sputum samples are 
then stained using similar techniques to tissue biopsies to 
  examine the specific type of cellular infiltrate in the   sputum. 
The principal output is the differential inflammatory cell 
count, expressed as a percentage, based on the manual 
counting of 400 cells (eosinophils, neutrophils, lymphocytes, 
  macrophages, epithelial cells). The upper limit of eosino-
philic proportion in normals is approximately 1.9% and this 
fraction rises up to seven-fold in asthmatics after allergen 
challenge, before exacerbations, and following inhaled 
corticosteroid withdrawal.14 This technique has been used 
to identify subpopulations of asthmatics who demonstrate 
neutrophilic rather than eosinophilic asthma, and are therefore 
less likely to respond to steroids.13 In patients with moderate 
to severe asthma, the absence of sputum eosinophilia cannot 
distinguish between patients who suffer from noneosino-
philic asthma versus those whose eosinophilia is controlled 
by   steroids. A recent study has shown that the eosinophilic 
proteins, eosinophil cationic protein and eosinophil per-
oxidase, can be identified in cultured macrophages that have 
consumed   apoptotic eosinophils.15 In patients, eosinophil 
cationic protein/eosinophil peroxidase-positive macrophages 
were increased in the sputum of moderate to severe asth-
matics treated with inhaled steroids regardless of sputum 
eosinophilia, in individuals who suffer from eosinophilia 
upon   steroid   withdrawal, and in patients with eosinophilic 
  bronchitis. Thus, sputum   macrophage eosinophil protein con-
tent is an indirect biomarker of   airway eosinophilia that can 
identify asthmatics whose disease stems from airway eosino-
philia, even in patients undergoing steroid treatment.15
The protein content of induced sputum may also have 
some value in diagnosing asthma. High mobility group box-1, 
a ligand of the receptor for advanced glycation end products 
(RAGE), is a mediator in many inflammatory disorders. High 
mobility group box-1 is increased in the sputum of asthmatic 
patients, along with endogenous secretory RAGE, a soluble 
receptor that inhibits RAGE signaling.16 Sputum induction 
is considerably less invasive than a tissue biopsy, but this 
technique is nonetheless uncomfortable for the patient. Given 
that many children are unwilling to undergo sputum collec-
tion at follow-up visits, this technique tends to be limited to 
Table 1 Advantages and disadvantages of currently used asthma biomarkers
Biomarker Advantage Disadvantage
Pulmonary function tests (PFTs)  
(Fev1, AHR)
Non-invasive, well validated, sensitive – ie,  
will detect all asthmatics, reproducible,  
PFTs will change rapidly with treatment.
Unable to identify sub-phenotypes of asthmatics,  
PFTs do not reflect pathology, PFTs cannot predict  
treatment response.
Tissue biopsy Definitive measure of airway  
inflammation.
Highly invasive, disconnect between cell counts and  
symptoms, time consuming, requires high level of  
expertise.
induced sputum (differential  
inflammatory cell counts)
Less invasive than tissue biopsy, reliable  
indicator of airway inflammation.
very uncomfortable process, limited to children .8 yrs, 
requires expertise, reproducibility problems.
exhaled nitric oxide  
(FeNO)
Non-invasive, simple measurement methods,  
indicates treatment (steroid) response.
Proven only for a sub-set of asthmatics, expensive  
equipment,  a single biomarker reflects a single pathology.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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patients aged eight years and older (although sputum induc-
tion has been performed successfully on younger children).14 
The techniques of sputum induction and processing are 
well validated, but they are time-consuming, require skilled 
people, and results are often difficult to reproduce and vary 
across centers.
Exhaled biomarkers
Less invasive means of obtaining airway biomarkers are 
desirable, particularly as diagnostic or disease monitoring 
tools in pediatric patients. The composition of exhaled 
breath is correlated with various disease states. This has been 
exploited by cancer researchers who have pioneered the use 
of gas sensor arrays, or “electronic noses”, to aid the diag-
nosis of lung cancer.17 Because asthma is also a disease of 
the airways, it follows that the composition of exhaled breath 
will also be altered in the disease. The advent of so-called 
“breathomics” promises to revolutionize the way clinicians 
diagnose and treat asthmatics.
Fractional exhaled nitric oxide
To date, fractional exhaled nitric oxide (FeNO) is the most 
widely used exhaled biomarker of airway inflammation 
in asthma. Levels of nitric oxide in exhaled breath can be 
measured relatively quickly in the clinic, although the gas 
analyzers required are expensive.14 FeNO is often increased 
in steroid-naïve asthmatics and severe asthmatics, and is cor-
related with airway eosinophilia.18,19 FeNO is derived from 
the action of inducible nitric oxide synthase expressed by the 
airway epithelium,20 although the precise mechanism of how 
eosinophilia triggers inducible nitric oxide synthase activity 
in epithelial cells is undefined. Advocates of FeNO use in 
asthma suggest that it can be used as a noninvasive biomarker 
to indicate likelihood of response to steroid therapy.21–25 
A defined schema has been proposed for FeNO-directed 
asthma diagnosis and treatment. Briefly, in steroid-naïve 
asthmatics, FeNO should be used as an indicator of steroid 
responsiveness. A low FeNO level of less than 25 parts per 
billion indicates that the patient is unlikely to suffer from 
eosinophilic asthma and is less likely to respond to steroids. 
A high FeNO (.50 parts per billion) strongly suggests 
airway eosinophilia and steroid responsiveness. In difficult 
asthmatics already undergoing inhaled corticosteroid treat-
ment, FeNO can indicate whether poor disease control is due 
to uncontrolled airway inflammation or to noninflammatory 
causes, thus assisting clinicians to direct inhaled corticoster-
oid dosage. Despite this logic, several randomized controlled 
trials have concluded that FeNO has little value over and 
above clinical symptoms when optimizing the dose of ste-
roid used for asthma treatment.26 It is important to note that 
each of the six trials reviewed used different FeNO values 
as cutoff points to direct treatment decisions, ranging from 
20 to 45 parts per billion. Because the predictive value of 
FeNO for steroid responsiveness varies greatly depending 
on the cutoff value used, it is difficult to compare the results 
of trials which used different designs. Nevertheless, taken 
together, these studies suggest that FeNO alone cannot 
provide reliable information on the exact dosage of inhaled 
corticosteroid required in a given patient. Rather, FeNO is 
best used to determine whether the present dose of inhaled 
corticosteroid is adequate to control airway inflammation.21 
If inadequate, clinicians may choose to increase the dose of 
inhaled corticosteroids or add additional anti-inflammatory 
therapies, eg, leukotriene receptor modifiers. There is a 
large variation in FeNO levels between individuals, which 
may reflect the natural heterogeneity in baseline epithelial 
nitric oxide synthase activity and/or the contribution of other 
noneosinophilic factors to epithelial nitric oxide synthase 
activity. Interindividual variation in FeNO combined with the 
inherent heterogeneity of asthma increases the background 
noise, which renders FeNO a relatively insensitive tool for 
guiding therapy in all asthmatics. However, FeNO values 
Table 2 Alternative biomarkers for asthma diagnosis and management
Biomarker source Advantages Disadvantages
exhaled breath condensate (eBC) – pH &  
proteins (Inflammatory markers; IL-6, IL-8, TNF-α,  
H2O2, leukotrienes, 8-isoprostane. Non-inflammatory  
markers; actin, cytokeratins, albumin)
Non-invasive, multiple biomarkers in sample  
therefore sub-phenotyping possible.
Collection techniques drastically affect  
proteins in sample, reproducibility  
a problem, salivary contamination, unproven 
clinical effectiveness.
Serum proteins (Leptin/adiponectin, eosinophillic  
cationic protein, chemokines, chitinases)
Less invasive, multiple biomarkers =  
sub-phenotyping, standardised collection  
and processing techniques.
Less sensitive and slower response  
to airway changes, unproven clinical  
effectiveness.
Urinary metabolites (.70) endpoints Non-invasive, multiple biomarkers =  
sub-phenotyping, standarised collection  
and processing, good sensitivity and specificity.
Unproven clinical effectiveness (although 
preliminary data is positive), limited access  
to NMR equipment.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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in an individual are highly reproducible, so it may be more 
successful to use personalized cutoff values for each subject, 
rather than using a single cutoff value for all patients.27 It is 
possible that there are certain subgroups of asthmatics in 
whom FeNO measurement would have an excellent signal 
to noise ratio. In the future, with improved phenotyping, 
identification of such subgroups may be possible.
Atopy, ie, the genetic predisposition to develop allergic 
diseases such as eczema, allergic rhinitis, and asthma, is 
a possible confounding factor when measuring FeNO in 
asthma. Atopy is often accepted as the major trigger of 
asthma, particularly in children, but its association with the 
disease may have been exaggerated. Epidemiological stud-
ies have demonstrated that the proportion of asthmatic cases 
attributable to atopy in the general population is usually less 
than 50% and many atopics do not develop asthma.28 Various 
studies demonstrate that FeNO is increased in atopic indi-
viduals with and without asthma, suggesting FeNO acts as a 
biomarker of atopy and the “allergic asthma” phenotype.29–32 
Contradictory studies have found that atopy, as defined by 
positive skin prick testing, or the presence of various allergic 
diseases, is not related to FeNO and thus elevated FeNO is 
a relatively specific marker of asthmatic disease.33,34 With 
such polarized opinion as to whether atopy is indeed a con-
founding factor, it is probably wise at present to consider the 
coexistence of atopy when assessing a patient’s asthmatic 
status based on FeNO.
exhaled breath condensate
The collection of exhaled breath condensate and subsequent 
measurement of inflammatory biomarkers is a relatively 
recent development. Exhaled breath condenses when it comes 
into contact with a cooled collector, allowing the collection 
of respiratory particles, droplets, and water vapor. The pH of 
exhaled breath condensate has been shown to relate to airway 
inflammation. Low exhaled breath condensate pH indicates 
poorly controlled eosinophilic asthma in a similar manner to 
high FeNO.25 It is unlikely that a single biomarker will be able 
to reflect the various pathologies present in a heterogeneous 
disease such as asthma. Therefore, additional markers of 
airway inflammation will be needed to provide information 
complementary to that gained from FeNO measurements. 
Many proteins are present in exhaled breath condensate, and 
this method has been proposed as a means to allow the objec-
tive proteomic analysis of exhaled breath. As with pH, several 
of these proteins are markers of oxidative stress, including 
cysteinyl leukotrienes, leukotriene B4, 8-isoprostane, and 
hydrogen peroxide, although inflammatory proteins, such 
as interleukin (IL)-6, IL-8, and tumor necrosis factor alpha 
may also be useful markers.14,35 Other proteins which do 
not obviously fit into any inflammatory pathway, including 
actin, cytokeratins, albumin, and hemoglobin, have also been 
shown to be increased in the exhaled breath condensate of 
asthmatic patients.36
Currently there is no standard type of condenser used 
to collect exhaled breath condensate. The differing surface 
properties of each condenser type causes significant variation 
in the nature of the particles collected, although exercise and 
environmental conditions also contribute.37 For this reason, 
standardization of collector apparatus and protocols are 
required to allow exhaled breath condensate measurements 
to be comparable between sites.
Non-exhaled biomarkers
Serum proteins
As described earlier, biomarker studies in asthma have tended 
to concentrate on changes to the composition of exhaled 
breath. Although primarily a disease of the airways, there 
is mounting evidence to suggest there is also a systemic 
component to asthma.38 If this is the case, then circulating 
metabolites may be able to act as biomarkers of airways 
disease. Blood collection, serum isolation, and analysis are 
highly standardized techniques of a minimally invasive nature 
and are therefore an ideal source of reproducible data. Serum 
proteins are already gaining credence as biomarkers in other 
inflammatory lung diseases. In COPD, for example, not all 
smokers develop the disease, so being able to identify those 
who are at risk would be useful. Studies have shown circulat-
ing levels of pulmonary and activation-regulated chemokine/
CCL-18 are increased in COPD patients,39 and those patients 
who show a rapid fall in FEV1 tend to have high circulating 
levels of fibrinogen.40 Even accepted markers of cardiac 
dysfunction, eg, cardiac troponin-T and N-terminal probrain 
natriuretic peptide, have been associated with increased 
mortality in patients with COPD, suggesting a cardiac 
component to the disease.3 Several serum biomarkers have 
been demonstrated to be associated with asthma, including 
eosinophil cationic protein. Eosinophil cationic protein levels 
increase in response to allergen challenge, and decrease after 
allergen avoidance or inhaled corticosteroid therapy, albeit in 
a less responsive manner than sputum eosinophils or FeNO.14 
However, in the clinic, serum eosinophil cationic protein 
levels do not reflect treatment-induced functional changes in 
chronic asthmatics, and serum eosinophil cationic protein is 
unable to predict steroid responsiveness.14 One randomized 
trial demonstrated that patients whose asthma management Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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was based on serum eosinophil cationic protein levels expe-
rienced no improvement in symptoms compared with those 
treated using traditional monitoring techniques.41 In addition, 
raised serum eosinophil cationic protein levels may not be 
a specific marker of asthma, as studies in pediatric patients 
have demonstrated serum eosinophil cationic protein is also 
raised in cystic fibrosis and viral bronchiolitis.42
Asthma is to a large extent a disease of gene-environment 
interaction. One important environmental factor is obesity, 
with several studies demonstrating an association with asthma. 
The leptin/adiponectin balance is an important regulator of 
body fat metabolism and this ratio is altered in obesity. Studies 
have shown that levels of circulating leptin and adiponectin 
are altered in obese and nonobese patients with asthma.43 
Interestingly, a recent study in a Swedish cohort demonstrated 
that obese patients who wheeze have reduced FeNO compared 
with obese patients without asthma symptoms.44 FeNO is 
not related to body mass index in patients without airways 
disease,44,45 suggesting the underlying disease mechanisms, 
and consequently asthma phenotype, may be different in 
patients with a high body mass index.
Other novel biomarkers are also altered in the circulation 
of patients with asthma. CCL-17 is a chemokine released 
from dendritic cells and epithelial cells after allergen con-
tact, and is involved in the recruitment of Th2 cells into the 
lungs. Sputum levels of CCL-17 are increased in the lungs 
of asthmatic adults,46 whilst serum levels of CCL-17 are 
increased in children with asthma and lowered in steroid-
treated children with asthma.47 The chitinase-like protein, 
YKL-40, has also been shown to be increased in the serum 
of adult asthmatics and is correlated with sputum levels and 
various clinical markers of asthma severity.48,49 In asthma, 
structural cells of the airway, including the epithelium, release 
various proinflammatory chemokines, such as IL-6 and IL-8, 
which trigger subsequent infiltration by immune cells. The 
epithelium also releases proteinases which are capable and 
necessary for the cleavage and activation of chemokinetic 
activity for molecules such as fas-ligand and IL−25.50,51 It 
is possible that circulating levels of these chemokines and 
proteinases may provide an early warning for an imminent 
asthma exacerbation, or even indicate the particular subtype 
of inflammation occurring in the patient.
Urinary metabolites
The aforementioned data suggest that the metabolism of 
patients with asthma is altered compared with normals. 
Urine is possibly the least invasive biofluid for biomarker 
measurements, and is therefore highly suitable for the study 
and assessment of asthma in young children. Clinical stud-
ies have shown urinary biomarkers are potentially useful 
in asthma. Levels of the downstream histamine metabolite, 
N-methylhistamine, is increased in the urine of patients with 
asthma, is increased after allergen challenge or exacerba-
tion, and is reduced in asthmatic children taking antiallergy 
medication.52,53
One recent study used nuclear magnetic resonance spec-
troscopy (NMR) to measure levels of 70 metabolites in the 
urine of children with and without asthma. NMR is an attrac-
tive method for urinary biomarker examination because it is 
able to provide qualitative and quantitative data on multiple 
compounds in a complex biofluid, without requiring signifi-
cant pretreatment of the sample. Urine was collected from 
control children without asthma, children with stable asthma 
in the outpatient department, and from children with unstable 
disease hospitalized for an asthma exacerbation. NMR exami-
nation of urinary metabolites showed a 94% success rate in 
identifying outpatient department asthmatic children versus 
children without asthma, and a similar success rate was seen 
when diagnosing an asthma exacerbation versus outpatient 
department asthma.54 This study suggests that measurement 
of urinary metabolites is a potentially valuable technique to 
help clinicians diagnose and monitor asthma in children.
Future for biomarkers in asthma
In recent years, it has become increasingly accepted that 
pulmonary function testing has its limitations. Spirometry can 
identify a broad spectrum of asthmatics, but it is incapable 
of discerning the various subtypes of disease and therefore 
which individuals will respond to normal treatment regimes. 
Tissue biopsies and inflammatory cell counting in induced 
sputum are accepted measures of determining airway inflam-
mation, but both techniques are invasive, expensive, and 
difficult to standardize, making them unsuitable for routine 
clinical use. Biomarkers hold the promise of being able to 
diagnose and monitor various subtypes of asthma rapidly 
and specifically in a noninvasive manner.
Before considering biomarkers for use in the clinic, we 
must appreciate that asthma is a heterogeneous disease. 
Expecting a single biomarker to improve the treatment of all 
asthmatics regardless of their underlying disease phenotype is 
unrealistic. The most well developed biomarker in current use 
is FeNO. However, as previously discussed, its utility is lost 
when it is applied to all asthmatics because of the underlying 
heterogeneity of the phenotypes. In practice, a panel of 
biomarkers is needed to indicate the various different 
underlying disease pathologies, thus enabling the definitive Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
85
Biomarkers of airway inflammation in asthma
and objective categorization of asthmatics into distinct 
subphenotypes (see Figure 1). Standardization of protocols 
is vital when designing a panel of asthma biomarkers for 
clinical use. FeNO is a promising biomarker, but at present 
there is disagreement about what is a normal or abnormal 
FeNO level. Defining appropriate cutoff points is crucial to 
guide the appropriate clinical response.
Exhaled breath condensate is a potentially rich source of 
airway biomarkers, but again standard collection protocols 
are required before use in the clinic is even considered. In 
contrast, protocols for biofluid (serum and urine) collection 
and processing are well developed, and indeed several studies 
have shown that monitoring systemic or secreted metabolites 
may be the best way to define multiple biomarkers for the 
diagnosis and design of treatment regimes for asthma.
To date, the majority of asthma biomarkers have reflected 
airways inflammation, but inflammation is not the only 
pathological component of the disease. Airways remodel-
ing plays a major role in asthma pathology, and so markers 
designed to indicate structural changes, such as epithelial 
damage, mucous hyperplasia, myofibroblast proliferation, 
and smooth muscle growth, may also prove useful to define 
a disease phenotype accurately. Regardless of the complexity 
or completeness of a future panel of asthma biomarkers, it is 
highly unlikely that they will completely replace pulmonary 
function testing in the clinic. Indeed, biomarker testing will be 
designed to complement rather than replace existing methods 
of clinical diagnosis and disease monitoring.
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